Receive stem cell therapy for free!Recruit 20 patients with hepatitis B (compensation period)

Wuhan Evening News August 2 (Correspondent Ning Yafei) Hepatitis B has seriously threatened patients' health and life, but there are different defects in the current treatment methods. Based on the clinical research project of hepatitis B (compensation period) clinical research projects for the treatment of hepatitis B (compensation period) in the early stage of the human umbilical cord source, Wuhan University People's Hospital (Hubei Provincial People's Hospital) infection was faced with Hubei, and 20 patients with hepatitis B sclerosis were recruited. Stem cell treatment.

The clinical project leader and Professor Jiang Ying'an in the infection of Wuhan University People's Hospital said that the clinical study of stem cells refers to the application of (or implanted) the human body after an in vitro -in vitro -in vitro stem or vitamin source for disease prevention or treatment. The basics and clinical transformation of stem cells are one of the most watched fields in today's life science research. It is one of the important breakthroughs of medical research in the 21st century. Wuhan University People's Hospital is the first batch of stem cell clinical research institutions in the country and Hubei Province.

Professor Jiang Ying'an introduced that the replacement therapy of intensive liver diseases such as cirrhosis is the focus and key means of clinical treatment, mainly because liver transplantation, artificial liver, stem cell transplantation therapy, etc. However, due to the high cost of liver transplantation, the limited supply of liver sources, and postoperative immune exclusion has limited the widespread use of liver transplantation. Artificial liver is a treatment method of "function replacement" by plasma replacement or molecular adsorption. In contrast, stem cells are multi -functional cells with self -renewal and differentiation ability. Occupible stem cell transplantation treatment of liver cirrhosis is becoming a treatment method with small damage, few complications, and obvious curative effects. The field provides hope for patients with cirrhosis.

In January 2019, the "Clinical Research Research on the Compensation Period of Hepatitis B's Hepatitis Hepatitis Hepatitis Hepatitis Hepatitis Hepatitis cirrhosis compensation period" project undertaken by Wuhan University People's Hospital was officially obtained by the China Medical Biotechnology Association and the National Stem Cell Clinical Research Expert Committee for review and filing. The first batch of clinical studies have been carried out for the first batch of patients with liver cirrhosis. At the same time, the hospital is participating in the General Hospital of the People's Liberation Army to conduct a "random, double blindness, placebo comparison with the effectiveness and safety of patients with dysplasia during the treatment of loses -compensation during the treatment of the navel cord. Multi-center "clinical research (ethical approval number: 2018-107-D).

It is reported that this issue of the People's Hospital of Wuhan University recruited 20 patients with hepatitis B sclerosis to Hubei and participate in the clinical trials of stem cell therapy for hepatitis B (compensation period).

1. From now on, all Hubei household registration patients who are aged 18-65 and are hepatitis B (compensation period) can be registered. To facilitate follow -up, patients in Wuhan are preferred.

2. After evaluation, 20 patients suitable for participating in this study will be included in clinical research, and various inspections and treatment involved in the project will be received for free (the content of the "Contents of the Intelligence Agreement" shall prevail).

3. Consultation and registration number: Dr. Yao, 13638685006 (WeChat is the same number, it is recommended to communicate through WeChat).

[Edit: Yu Lina]

- END -